Magrolimab
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-MAGROLIMAB |
|---|---|
| Type | Drug |
| Aliases | Магролімаб |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-AML-2025 |
Drug Facts
| Class | Anti-CD47 humanized IgG4 monoclonal antibody (innate-immunity / macrophage-checkpoint inhibitor) |
|---|---|
| Mechanism | Humanized IgG4 monoclonal antibody binding CD47, a "do-not-eat-me" signal expressed on tumor cells that engages SIRPα on macrophages to inhibit phagocytosis. Blockade of CD47-SIRPα releases macrophages to phagocytose tumor cells (innate-immunity macrophage-checkpoint inhibition). Synergizes with pro-phagocytic signals from azacitidine / chemo-induced calreticulin exposure. Investigated principally in AML / MDS (TP53-mutant focus) and DLBCL. |
| Typical dosing | HISTORICAL — for archival / comparator-trial reference only. In clinical trials magrolimab was given IV with a priming-dose strategy (1 mg/kg priming dose to prevent on-target hemolytic anemia, then escalation to 30 mg/kg weekly maintenance) typically combined with azacitidine 75 mg/m² SC/IV days 1-7 of 28-day cycles. NEVER approved; no labeled dose exists. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-29 |
Notes
STATUS: DEVELOPMENT DISCONTINUED — Gilead Sciences (acquired magrolimab via Forty Seven Inc, $4.9B, 2020) announced on February 14, 2024 the complete discontinuation of magrolimab AML and MDS development programs. DLBCL and solid-tumor (CRC, ovarian, bladder) programs were wound down through mid-late 2024. The decision followed: (1) FDA partial clinical hold on ENHANCE-2 (Phase III 1L TP53-mutant AML, magro+aza vs venetoclax+aza) in Aug 2023 — apparent excess mortality. (2) ENHANCE-3 (Phase III 1L AML unfit for intensive chemo, magro+ven+aza vs placebo+ven+aza) crossed pre-specified futility boundary at IDMC review Jan 2024. (3) Independent Data Monitoring Committee recommendation to halt all magrolimab AML / MDS studies. Magrolimab was the most clinically advanced anti-CD47 antibody; its failure raises questions about CD47-SIRPα as a therapeutic axis in myeloid malignancies generally — but next-generation CD47 / SIRPα agents (lemzoparlimab, evorpacept, AO-176) and bispecifics remain in earlier-phase development. KB retains this entry to: (a) document the failed program for clinical decision support (recommendation: do NOT seek magrolimab access for any patient — none available; d...
Used By
No reverse references found in the YAML corpus.